Phase 1/2Data readout

NUC-7738 (ProTide) +/- pembrolizumab

Solid tumor/s, Cancer, Melanoma

NCNANucana

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: NUC-7738 (ProTide) +/- pembrolizumab
Development stage: Phase 1/2
Event type: Data readout
Indication: Solid tumor/s, Cancer, Melanoma

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for NUC-7738 (ProTide) +/- pembrolizumab in Solid tumor/s, Cancer, Melanoma. The expected timing is based on the latest available company guidance and may change.

Development notes

05/14/26:- IND cleared. NuTide:701 recruitment, final data, and FDA guidance expected in 2026. 08/13/26:- NuTide:701 recruitment completed. Final Phase 2 data and FDA guidance are expected later in 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source